Sagent Pharmaceuticals, Inc. (SGNT) Reports Q2 EPS Loss of $0.37, Revenues Grow 205%

Go back to Sagent Pharmaceuticals, Inc. (SGNT) Reports Q2 EPS Loss of $0.37, Revenues Grow 205%